Literature DB >> 31949746

The expressions of CD133, ALDH1, and vasculogenic mimicry in osteosarcoma and their clinical significance.

Zhengqi Bao1, Zenong Cheng2,3, Damin Chai2,3.   

Abstract

BACKGROUND AND
PURPOSE: Osteosarcoma is an aggressive malignant bone tumor in children and adolescents, which is more likely to recur and metastasize at the early stages. Cancer stem cells (CSC, CD133 is a biomarker of cancer stem cells), angiogenesis, and vasculogenic mimicry (VM) are closely related to tumor metastasis and recurrence. In this study, we investigated the associations among CD133, aldehyde dehydrogenase 1 (ALDH1), and VM in osteosarcoma, and their associations with clinical characteristics.
METHODS: Positive rates of CD133, ALDH1, and VM in 96 whole osteosarcoma tissue samples were detected by immunohistochemistry (IHC) and histochemistry staining. Patients' clinical data were also collected.
RESULTS: Positive rates of CD133, ALDH1, and VM were significantly higher in osteosarcoma tissues compared with the control tissues. Positive rates of CD133, ALDH1, and VM were positively associated with lymph node metastasis, distant metastasis, Enneking stages, and patients' overall survival (OS). A multivariate analysis indicated that the positive rates of CD133, ALDH1, and VM, as well as the Enneking stages were independent prognostic factors of osteosarcoma.
CONCLUSION: The positive rates of CD133, ALDH1, and VM could represent potential biomarkers for metastasis and prognosis, which suggests these molecules might be promising therapeutic targets for osteosarcoma. IJCEP
Copyright © 2018.

Entities:  

Keywords:  CD133; Osteosarcoma; aldehyde dehydrogenase 1; prognosis; vasculogenic mimicry

Year:  2018        PMID: 31949746      PMCID: PMC6962889     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  31 in total

1.  Microcirculation patterns in different stages of melanoma growth.

Authors:  Shiwu Zhang; Hua Guo; Danfang Zhang; Wenzhi Zhang; Xiulan Zhao; Zhiyong Ren; Baocun Sun
Journal:  Oncol Rep       Date:  2006-01       Impact factor: 3.906

2.  Prognostic value of ALDH1 expression in lung cancer: a meta-analysis.

Authors:  Wei Huo; Min Du; Xinyan Pan; Xiaomin Zhu; Zhimin Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

3.  In vitro characterization of CD133lo cancer stem cells in Retinoblastoma Y79 cell line.

Authors:  Rohini M Nair; Murali Ms Balla; Imran Khan; Ravi Kiran Reddy Kalathur; Paturu Kondaiah; Geeta K Vemuganti
Journal:  BMC Cancer       Date:  2017-11-21       Impact factor: 4.430

4.  CD133 expression in osteosarcoma and derivation of CD133⁺ cells.

Authors:  Ji Li; Xiao-Yan Zhong; Zong-Yu Li; Jin-Fang Cai; Lin Zou; Jian-Min Li; Tao Yang; Wei Liu
Journal:  Mol Med Rep       Date:  2012-12-13       Impact factor: 2.952

5.  ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer.

Authors:  Xiao-shan Li; Qing Xu; Xiang-yang Fu; Wei-sheng Luo
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

6.  Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133+ osteosarcoma cancer stem cells.

Authors:  Miaozhong Ni; Min Xiong; Xinchao Zhang; Guoping Cai; Huaiwen Chen; Qingmin Zeng; Zuochong Yu
Journal:  Int J Nanomedicine       Date:  2015-03-31

7.  Lung cells support osteosarcoma cell migration and survival.

Authors:  Shibing Yu; Mitchell Stephen Fourman; Adel Mahjoub; Jonathan Brendan Mandell; Jared Anthony Crasto; Nicholas Giuseppe Greco; Kurt Richard Weiss
Journal:  BMC Cancer       Date:  2017-01-25       Impact factor: 4.430

8.  Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma.

Authors:  Lan Yu; Bo Zhu; Shiwu Wu; Lei Zhou; Wenqing Song; Xiaomeng Gong; Danna Wang
Journal:  Diagn Pathol       Date:  2017-03-02       Impact factor: 2.644

9.  Aberrant expression of CD133 in non-small cell lung cancer and its relationship to vasculogenic mimicry.

Authors:  Shiwu Wu; Lan Yu; Danna Wang; Lei Zhou; Zenong Cheng; Damin Chai; Li Ma; Yisheng Tao
Journal:  BMC Cancer       Date:  2012-11-21       Impact factor: 4.430

10.  Evaluation of the correlation of vasculogenic mimicry, ALDH1, KAI1 and microvessel density in the prediction of metastasis and prognosis in colorectal carcinoma.

Authors:  Bo Zhu; Lei Zhou; Lan Yu; Shiwu Wu; Wenqing Song; Xiaomeng Gong; Danna Wang
Journal:  BMC Surg       Date:  2017-04-21       Impact factor: 2.102

View more
  5 in total

Review 1.  Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments.

Authors:  Xiaoxu Wei; Yunhua Chen; Xianjie Jiang; Miao Peng; Yiduo Liu; Yongzhen Mo; Daixi Ren; Yuze Hua; Boyao Yu; Yujuan Zhou; Qianjin Liao; Hui Wang; Bo Xiang; Ming Zhou; Xiaoling Li; Guiyuan Li; Yong Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2021-01-04       Impact factor: 27.401

2.  The prognostic role of CD133 expression in patients with osteosarcoma.

Authors:  Nuo Xu; Yijun Kang; Wanchun Wang; Jian Zhou
Journal:  Clin Exp Med       Date:  2020-02-12       Impact factor: 3.984

Review 3.  Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents.

Authors:  He-Ming Zhou; Ji-Gang Zhang; Xue Zhang; Qin Li
Journal:  Signal Transduct Target Ther       Date:  2021-02-15

4.  Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR.

Authors:  Bosen You; Yin Sun; Jie Luo; Keliang Wang; Qing Liu; Ruizhe Fang; Bingmei Liu; Fuju Chou; Ronghao Wang; Jialin Meng; Chi-Ping Huang; Shuyuan Yeh; Chawnshang Chang; Wanhai Xu
Journal:  Oncogene       Date:  2021-01-28       Impact factor: 9.867

Review 5.  Biological evidence of cancer stem-like cells and recurrent disease in osteosarcoma.

Authors:  Camille Jubelin; Javier Muñoz-Garcia; Denis Cochonneau; Emilie Moranton; Marie-Françoise Heymann; Dominique Heymann
Journal:  Cancer Drug Resist       Date:  2022-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.